Aeglea BioTherapeutics Announces Proposed Public Offering
April 27, 2020 16:01 ET
|
Aeglea BioTherapeutics, Inc.
AUSTIN, Texas, April 27, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (Nasdaq: AGLE), a clinical-stage biotechnology company developing next-generation human enzyme therapeutics as...
Aeglea BioTherapeutics Announces Approval of Clinical Trial Application for its Novel Engineered Human Enzyme Designed to Treat Homocystinuria (ACN00177)
April 08, 2020 07:30 ET
|
Aeglea BioTherapeutics, Inc.
AUSTIN, Texas, April 08, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing next-generation human enzyme therapeutics as solutions...
Aeglea BioTherapeutics Reports Fourth-Quarter and Full-Year 2019 Financial Results, Highlights Recent Milestones
February 24, 2020 07:30 ET
|
Aeglea BioTherapeutics, Inc.
Company Expects to Complete Enrollment in Phase 3 Trial for Patients with Arginase 1 Deficiency in Third Quarter of 2020, with Topline Data Expected in First Quarter of 2021 Phase 1/2 Trial for...
Aeglea BioTherapeutics Submits CTA Application for its Novel Engineered Human Enzyme Designed to Treat Homocystinuria (ACN00177)
January 13, 2020 07:00 ET
|
Aeglea BioTherapeutics, Inc.
AUSTIN, Texas, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing next-generation human enzyme therapeutics as solutions...
Aeglea BioTherapeutics to Present at 38th Annual J.P. Morgan Healthcare Conference
January 06, 2020 16:05 ET
|
Aeglea BioTherapeutics, Inc.
AUSTIN, Texas, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing next-generation human enzyme therapeutics as solutions...
Aeglea BioTherapeutics to Participate in Upcoming Investor Conferences
November 26, 2019 08:30 ET
|
Aeglea BioTherapeutics, Inc.
AUSTIN, Texas, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that engineers next-generation human enzymes to provide solutions...
Aeglea BioTherapeutics Reports Third Quarter 2019 Financial Results and Corporate Highlights
November 06, 2019 08:30 ET
|
Aeglea BioTherapeutics, Inc.
AUSTIN, Texas, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that engineers next-generation human enzymes to provide solutions...
Aeglea BioTherapeutics Strengthens Leadership Team with Appointment of Ravi M. Rao as Chief Medical Officer and Michael C. Hanley as Chief Commercial Officer
November 04, 2019 08:30 ET
|
Aeglea BioTherapeutics, Inc.
AUSTIN, Texas, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that engineers next-generation human enzymes to provide solutions...
Aeglea BioTherapeutics to Present at 21st Annual H.C. Wainwright Global Investment Conference
September 05, 2019 08:30 ET
|
Aeglea BioTherapeutics, Inc.
AUSTIN, Texas, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that engineers next-generation human enzymes to provide solutions...
Aeglea BioTherapeutics Announces Positive 20-Dose Data for Pegzilarginase in Patients with Arginase 1 Deficiency at the 2019 SSIEM Symposium
September 03, 2019 06:00 ET
|
Aeglea BioTherapeutics, Inc.
Sustained Control of Plasma Arginine Accompanied by Clinical Response; Overall Clinical Responder Rate of 79% Management to Host Conference Call at 9:00 a.m. ET on Tuesday, September 3 AUSTIN,...